HER2 IHC 3+ staining was observed in 15 (4.7%) of the 320 tumor samples analyzed and HER2 IHC 2+ in 26 (8.1%; Table 1). Low HER2 expression (IHC 0 or 1+) was detected in the 279 (87.2% ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Lunit’s model demonstrated 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry ... and 26-month OS. HER-2-targeted therapy uses monoclonal antibodies (mAb) or ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).